Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial

Radiotherapy and Oncology

Volumn 100, Issue 1, 2011, Pages 101-107

  Werkhoven, Erik Van ^a   Hart, Guus ^a   Tinteren, Harm Van ^a   Elkhuizen, Paula ^a   Collette, Laurence ^b   Poortmans, Philip ^c   Bartelink, Harry ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c Institute Verbeeten   (Netherlands)

Author keywords

Boost; Breast cancer; Breast conserving therapy; Decision making; Nomogram

Indexed keywords

TAMOXIFEN;

BREAST CANCER; BREAST CONSERVING THERAPY; BREAST FIBROSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NOMOGRAM; PRIORITY JOURNAL; RADIATION DOSE; REVIEW;

EID: 80051801074     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.07.004     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2005 2087 2106
2. H. Bartelink, J.C. Horiot, and P. Poortmans Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation N Engl J Med 345 2001 1378 1387
3. H. Bartelink, J.C. Horiot, and P.M. Poortmans Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial J Clin Oncol 25 2007 3259 3265 (Pubitemid 47325610)
4. N. Antonini, H. Jones, and J.C. Horiot Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882 Radiother Oncol 82 2007 265 271 (Pubitemid 46341468)
5. M.A. Bollet, B. Sigal-Zafrani, and V. Mazeau Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first Radiother Oncol 82 2007 272 280 (Pubitemid 46350796)
6. B.M. Beadle, W.A. Woodward, and T.A. Buchholz The impact of age on outcome in early-stage breast cancer Semin Radiat Oncol 21 2011 26 34
7. P.H.M. Elkhuizen, H.J. van Slooten, and P.C. Clahsen High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European organization for research and treatment of cancer breast cancer cooperative group study J Clin Oncol 18 2000 1075 1083 (Pubitemid 30123786)
8. P.M. Poortmans, L. Collette, and J.-C. Horiot Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscipically incomplete lumpectomy: 10-year results of the randomized EORTC boost trial Radiother Oncol 90 2009 80 88
9. B. Kreike, H. Halfwerk, and N. Armstrong Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients Clin Cancer Res 15 2009 4181 4190
10. M. Morrow Margins in breast-conserving therapy: have we lost sight of the big picture? Expert Rev Anticancer Ther 8 2008 1193 1196
11. H.A. Jones, N. Antonini, and A.A. Hart Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial J Clin Oncol 27 2009 4939 4947
12. M. Sanghani, E. Balk, B. Cady, and D. Wazer Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool Am J Clin Oncol 30 2007 473 480 (Pubitemid 47537946)
13. M. Sanghani, P.T. Truong, and R.A. Raad Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy J Clin Oncol 28 2010 718 722
14. S. Collette, L. Collette, and T. Budiharto Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost' Eur J Cancer 44 2008 2587 2599
15. F.E. Harrell Regression modeling strategies, with applications to linear models, survival analysis and logistic regression 2001 Springer New York
16. F.E. Harrell, K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387 (Pubitemid 26072233)
17. M. Gonen, and G. Heller Concordance probability and discriminatory power in proportional hazards regression Biometrika 92 2005 965 970 (Pubitemid 41681247)
18. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria; 2010. ISBN 3-900051-07-0.
19. Mo Q, Gonen M, Heller G. CPE: Concordance Probability estimates in survival analysis; 2010. R package version 1.4.1.
20. A. Iasonos, D. Schrag, G.V. Raj, and K.S. Panageas How to build and interpret a nomogram for cancer prognosis J Clin Oncol 26 2008 1364 1370
21. E.W. Steyerberg Clinical prediction models: a practical approach to development, validation, and updating 2009 Springer New York
22. U. Rudloff, L.M. Jacks, and J.I. Goldberg Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ J Clin Oncol 28 2010 3762 3769
23. J.L. Guinot, S. Roldan, and M. Maroñas Breast-conservative surgery with close or positive margins: can the breast be preserved with high-dose-rate brachytherapy boost? Int J Radiat Oncol Biol Phys 68 2007 1381 1387 (Pubitemid 47176793)
24. M.E. Peterson, D.J. Schultz, C. Reynolds, and L.J. Solin Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience Int J Radiat Oncol Biol Phys 43 1999 1029 1035 (Pubitemid 29144790)
25. M. Mannino, and J.R. Yarnold Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol 90 2009 14 22
26. The START Trialists Group The UK Standardization of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial Lancet 371 2008 1098 1107
27. T.J. Whelan, J.P. Pignol, and M.N. Levine Long-term results of hypofractionated radiation therapy for breast cancer N Engl J Med 362 2010 513 520
28. D. Williamson, R. Dinniwell, and S. Fung Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ Radiother Oncol 95 2010 317 320
29. T. Hijal, Fournier-Bidoz, and P. Fournier-Bidoz Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy Radiother Oncol 94 2010 300 306
30. H.P. Van der Laan, C.W. Hurkmans, A. Kuten, and H.A. Westenberg Current technological clinical practice in breast radiotherapy; results of a surbey in EORTC Radiation Oncology Group affiliated institutions Radiother Oncol 94 2010 280 285
31. B.V. Offersen, M. Overgaard, N. Kroman, and J. Overgaard Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review Radiother Oncol 90 2009 1 13
32. C. Polgar, E. Van Limbergen, and R. Poetter Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working Group based on clinical evidence (2009) Radiother Oncol 94 2010 264 273